Is there a role for digoxin in atrial fibrillation without heart failure?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Digoxin is a widely prescribed medication for managing atrial fibrillation.
• Established indications include sinus rhythm restoration, recurrence prevention, and ventricular rate control.
• Concerns exist regarding unconfirmed efficacy and potential increased mortality in specific patient groups.

Purpose of the Study:

• To critically review the established and potential roles of digoxin in atrial fibrillation management.
• To specifically examine the evidence for digoxin's use in patients with atrial fibrillation but without concomitant heart failure.
• To assess the safety profile, including mortality risks, associated with digoxin in this patient population.

Main Methods:

• Literature review of existing placebo-controlled studies.
• Analysis of recent reports and observational data concerning digoxin use in atrial fibrillation.
• Evaluation of evidence supporting or refuting digoxin's efficacy for primary indications.

Main Results:

• Evidence supporting digoxin's efficacy in restoring sinus rhythm, preventing recurrence, or controlling ventricular rate in atrial fibrillation is not robustly confirmed by placebo-controlled trials.
• Recent data indicate a potential association between digoxin use and increased mortality in atrial fibrillation patients who do not have heart failure.
• The established indications for digoxin in atrial fibrillation lack definitive confirmation from high-quality clinical studies.

Conclusions:

• The clinical utility and safety of digoxin in atrial fibrillation, particularly in patients without heart failure, require careful consideration due to limited supporting evidence and emerging safety concerns.
• Further rigorous, placebo-controlled studies are needed to definitively establish the benefits and risks of digoxin in managing atrial fibrillation.
• Clinicians should weigh the unconfirmed benefits against potential risks, including mortality, when prescribing digoxin for atrial fibrillation without heart failure.